Glenmark gets FDA nod for skin ointment; shares up slightly
Glenmark Pharmaceuticals has received the final approval from the US health regulator USFDA for triamcinolone acetonide ointment, used in treatment of various skin conditions.
Glenmark Pharmaceuticals has received the final approval from the US health regulator USFDA for triamcinolone acetonide ointment, used in treatment of various skin conditions.
"Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for triamcinolone acetonide ointment USP, 0.5%," it said in a BSE filing.
The approval has been granted for generic version of triamcinolone acetonide ointment USP, 0.5% of Perrigo New York, Inc. This ointment is used to treat various skin conditions including eczema, dermatitis, allergies and rash.
Quoting IMS sales data for the 12 months to May, Glenmark said Triamcinolone Acetonide Ointment achieved annual sales of around $4.4 million.
The company's current portfolio consists of 116 products authorised for distribution in the US and 61 Abbreviated New Drug Application (ANDA) pending approval with the USFDA.
Shares of Glenmark Pharmaceuticals were trading 0.38% up at Rs 868.35 in the morning trade on BSE while the 30-share Sensex was trading down 0.55%.